[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Unity Health Toronto\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":721},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,60,0,25,[9,51,85,116,141,166,193,224,264,297,326,351,385,414,447,476,499,528,551,572,597,619,648,674,696],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100652936","phase-3-strategies-for-the-management-of-atrial-fibrillation-in-patients-receiving-dialysis-2-safe-d2-100652936",false,"NCT07779746","Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis 2 (SAFE-D2)","SAFE-D2","Inclusion criteria\n\nTo be eligible to participate in this trial, participants need to satisfy ALL these inclusion criteria:\n\n1. Age ≥18 years,\n2. Kidney failure treated with hemodialysis or peritoneal dialysis for at least 90 days,\n3. A history of non-valvular AF or atrial flutter (AFL) defined as one of the following:\n\n   1. AF\u002FAFL on an ECG at enrollment.\n   2. ≥2 episodes of AF\u002FAFL on cardiac diagnostics with each episode lasting ≥30 seconds and occurring ≥24 hours apart.\n   3. One episode of AF\u002FAFL on cardiac diagnostics lasting ≥30 seconds, plus ≥1 separate documented episode in the medical record.\n   4. One episode of AF (reported by cardiac diagnostics or documented in the medical record) plus treatment with an oral anticoagulant for stroke prevention as a result of AF\u002FAFL; or\n   5. AF\u002FAFL documented on one occasion in a cardiologist report.\n4. Meet the CHA2DS2-VASc criteria (i.e. ≥2 for men and ≥3 for women)\n\nExclusion Criteria\n\nPotential participants must have NONE of the following exclusion criteria:\n\n1. Mitral stenosis described as moderate or severe.\n2. Anticoagulation indicated for a reason other than atrial fibrillation.\n3. Receipt of aspirin at a dose of \\>160 mg daily.\n4. Ongoing requirement at screening for a strong CYP3A4\u002FP-gp inhibitor or inducer that cannot be discontinued, substituted, or otherwise managed safely.\n5. Ongoing requirement for dual antiplatelet therapy at the time of screening that, in the judgement of the treating clinician, is expected to remain necessary after randomization and cannot be safely de-escalated to single antiplatelet therapy in the event of randomization to apixaban.\n6. Known clinically significant coagulopathy, or other bleeding risk that, in the judgment of the treating physician, renders oral anticoagulation unsafe.\n7. A major bleeding event in the 30 days prior to study enrollment, or any active and clinically significant bleeding.\n8. Current pregnancy or breastfeeding.\n9. Anticipated life expectancy \\\u003C 6 months.\n10. A scheduled live donor kidney transplant in the next 6 months.\n11. Co-enrollment in a clinical trial where the intervention is deemed to interfere with the adherence, safety or efficacy of the SAFE-D2 treatment strategies\n12. The treating clinical team has determined that long-term OAC is clearly indicated such that randomization to the no OAC strategy would not be clinically acceptable.\n13. The treating clinical team has determined that long-term OAC is clearly contraindicated such that randomization to the apixaban strategy would not be clinically acceptable.","ALL","18 Years",{"count":20,"type":21},848,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","People receiving dialysis are more likely to develop atrial fibrillation (AF), an irregular heartbeat that increases the risk of stroke. Blood-thinning medications (anticoagulants) are commonly used to prevent strokes in people with AF, but it is not known whether they are beneficial for people receiving dialysis because this group has not been well represented in previous clinical trials. As a result, healthcare providers do not have clear evidence to guide treatment decisions.\n\nThe SAFE-D2 study will compare two approaches to preventing stroke in adults receiving maintenance hemodialysis or peritoneal dialysis who have non-valvular AF and are at increased risk of stroke. Participants will be randomly assigned (by chance) to receive either apixaban, an oral blood thinner, or no oral anticoagulant, while continuing to receive their usual dialysis and medical care.\n\nThe main goal of the study is to determine whether apixaban is more effective than no oral anticoagulant at reducing the risk of stroke or blood clots traveling to other parts of the body (systemic embolism). The study will also compare the two approaches with respect to survival, heart-related complications, major bleeding and other bleeding events, hospitalizations, dialysis access complications, quality of life, and the overall balance of benefits and risks.\n\nApproximately 848 participants from Canada, Brazil, and Israel will take part in the study. The results of SAFE-D2 are expected to provide important evidence to help patients, families, and healthcare providers make informed decisions about stroke prevention for people receiving dialysis who have atrial fibrillation.",[27,28,29,30],"Atrial Fibrillation","Atrial Flutter","End Stage Kidney Disease (ESRD)","Dialysis Patients",[32,33,34,35,36,37,38],"atrial fibrillation","end stage renal disease","end stage kidney disease","dialysis","oral anticoagulation","apixaban","no oral anticoagulation","NOT_YET_RECRUITING","2026-08-18",{"date":42,"type":43},"2026-08-21","ACTUAL",{"date":45,"type":21},"2026-11",{"date":47,"type":21},"2032-11",{"name":49,"class":50},"Unity Health Toronto","OTHER",{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100617152","phase-3-adaptive-platform-trial-of-treatments-for-respiratory-infections-in-community-settings-treatresp-100617152","NCT07314905","Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)","Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings","TreatResp","Inclusion Criteria:\n\n* 18 years or older\n* A positive test (PCR or RAT) for one of the pathogens included in the trial's domains (influenza A\u002FB, or other future specified respiratory pathogens),\n* Enrolled within 5 days of symptoms onset. However, this window may vary depending on the domain or specific interventions within each domain (for example 72 hours for Baloxavir).\n* At least two symptoms commonly associated with respiratory infections, including:\n\n  * rhinitis\n  * cough\n  * wheezing\n  * sore throat\n  * nasal congestion\n  * shortness of breath\n  * fatigue\n  * rapid breathing\n  * excessive mucus production\n  * loss of smell or taste\n  * hemoptysis\n  * trouble sleeping or insomnia due to breathing difficulties\n  * fever (defined for purposes of this study as \\>37.5°C\u002F 41).\n\nExclusion Criteria:\n\n* Admitted to hospital or in an ED for more than 24 hours\n* Previously randomized to TreatResp within the past 12 months\n* Currently participating in a clinical trial of a therapeutic agent for acute respiratory pathogen infection that is not\u002Fsuspected not compatible with the study therapeutics\n* Already taking a study therapeutic or contraindication to a study therapeutic\n* Inability for participant or caregiver to provide informed consent.\n\nAdditional eligibility criteria will be applied based on the intervention assigned. For instance, if a participant is randomized to an antiviral treatment, they must not have contraindications specific to that antiviral. This ensures that each treatment is evaluated in a population for whom it is most appropriate and safe.\n\nBaloxavir exclusion:\n\n* Has a known or suspected pregnancy\n* Is breastfeeding\n* Is of childbearing potential and is not willing to use a highly effective contraceptive\n* Has advanced chronic kidney disease (CKD stage 3: eGFR ≥30 to \\\u003C60 mL\u002Fmin, and severe renal impairment (eGFR \\\u003C30 ml\u002Fmin, CKD stage 4-5)\n* Has severe hepatic impairment, or requires a live viral vaccine within the next seven days\n* Has a significant impaired immunity (e.g., due to long-term oral steroids, chemotherapy, or an immune disorder)\n* Requires immediate antiviral treatment or hospitalization as per the clinician's judgment\n* Is allergic to trial medications\n* Is scheduled for elective surgery or procedures requiring general anesthesia within the next two weeks\n* Is co-infected with viruses of interest\n* Received a live viral vaccine within the last 14 days",{"count":60,"type":21},264,[24],"TreatResp is a double-blind, individually randomized, multi-centre adaptive platform trial. TreatResp aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and outcomes of therapeutics for respiratory pathogens in non-hospitalized patients. Participants will be randomized to receive usual care (i.e., supportive care and symptom relief) or a study therapeutic, which will be determined by the TreatResp Therapeutics Committee. The primary outcomes being evaluated is time to recovery.",[64,65,66,67],"Influenza A","Influenza B","SAR-CoV-2","Acute Respiratory Infections (ARIs)",[69,70,64,65,71,72,73,74,75],"COVID-19","SARS-CoV-2","Influenza","Respiratory pathogens","Respiratory infections","Adaptative Platform Trials (APT)","acute respiratory infections (ARIs)","RECRUITING","2026-08-14",{"date":40,"type":43},{"date":80,"type":43},"2026-04-29",{"date":82,"type":21},"2027-04-24",{"name":49,"class":50},1,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":97,"conditions":98,"keywords":102,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":84},"100486430","integrated-suicide--trauma-therapy-for-suicide-risk-100486430","NCT05613972","Integrated Suicide & Trauma Therapy for Suicide Risk","Using Integrated Suicide and Trauma Therapy to Reduce Suicide Risk Among Adults With a History of Childhood Trauma","ISTT","Inclusion Criteria:\n\n* Beck Scale for Suicidal Ideation \\> 10\n* Presence of childhood trauma defined by a minimum moderate score on any of the Childhood Trauma Questionnaire subscales (emotional abuse, physical, abuse, sexual abuse, emotional neglect, and physical neglect\n* any psychiatric diagnosis as long as there are no impairments that limit consent or understanding of ISTT (e.g. active psychosis)\n* Ability to provide informed consent\n* Not receiving other psychotherapy concurrently\n* Ability to undergo psychotherapy in English\n\nExclusion Criteria:\n\n* The presence of cognitive impairment and\u002For active psychosis that would limit consent or understanding of ISTT\n* Unwilling or unable to provide informed consent",{"count":94,"type":21},20,[96],"NA","The investigators have developed a novel suicide intervention, Integrated Suicide and Trauma Therapy (ISTT). ISTT combines Brief-Skills for Safer Living (Brief-SfSL)-a promising method to enhance coping skills and reduce suicidality-with a trauma therapy component to alleviate the specific impacts of childhood trauma on suicide risk. The aim of this pilot is to test 12-weeks of ISTT to alleviate suicide risk among individuals with a history of childhood trauma and current suicidality.",[99,100,101],"Suicide","Trauma","Major Depressive Disorder",[103,104,105,106,107],"Childhood trauma","Early life adversity","Adverse childhood experiences","Suicide intervention","Psychotherapy","2026-08-13",{"date":110,"type":43},"2026-08-17",{"date":112,"type":43},"2025-12-08",{"date":114,"type":21},"2027-07",{"name":49,"class":50},{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":84},"100560036","brief-skills-for-safer-living-brief-sfsl-100560036","NCT06571916","Brief Skills for Safer Living (Brief-SfSL)","Investigating the Efficacy of a Novel Therapy for Suicide Risk in Adults: A Randomized Controlled Trial of an Intensive Single Session of \"Brief Skills for Safer Living\"","Inclusion Criteria:\n\n* Suicidal ideation in the past week\n* Access to a computer or phone with a camera\n* Access to internet\n* Access to an emergency contact and hospital within commuting distance\n* Not receiving other psychotherapy\u002Fcounselling services concurrently\n* Willing to have the session recorded to determine therapy fidelity\n* Any psychiatric diagnosis is allowed\n* Follow-up visits with a psychiatrist and\u002For family doctor where a psychotherapeutic modality (e.g., Dialectical Behavioural Therapy, psychodynamic therapy, etc.) is not being used are allowable\n\nExclusion Criteria:\n\n* Inability to undergo psychotherapy in English\n* Presence of cognitive impairment that would limit consent and understanding of Brief Skills for Safer Living or study procedures\n* Active psychosis that impairs capacity to consent, understand study procedures, or participate\n* Unwilling or unable to provide informed consent\n* Previously enrolled in the Brief-SfSL pilot study\n* Unwilling or unable to communicate verbally",{"count":124,"type":21},150,[96],"The goal of this project is to assess the efficacy of Brief-Skills for Safer Living (Brief-SfSL) in a randomized control trial. The investigators will be testing 150 participants Canada-wide, half of which will be randomized to receive Brief-SfSL (B-TAU) and the other half will be randomized to receive Brief-SfSL after a 3 month waitlist (WL-TAU). The main questions this study seeks to answer are:\n\n* Is B-TAU more efficacious than WL-TAU for reducing suicidal thoughts at 3 months?\n* Is B-TAU more efficacious than WL-TAU at 3 months for reducing depression severity, anxiety, and anhedonia?\n* Is B-TAU more efficacious than WL-TAU at 3 months for improving social connectedness, emotional regulation, functioning (work, life, social), executive control and social problem-solving?\n* Are adverse events equivalent between B-TAU and WL-TAU at 3 months?",[128,99,129],"Suicide Prevention","Suicide and Self-harm",[131,132],"suicide","psychotherapy","2026-07-31",{"date":135,"type":43},"2026-08-04",{"date":137,"type":43},"2025-11-17",{"date":139,"type":21},"2028-12-31",{"name":49,"class":50},{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":84},"100616132","phase-2-ecstasy-to-alleviate-severe-chronic-neuropathic-pain-trial-100616132","NCT07301632","Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial","Ecstasy to Alleviate SEvere Chronic Neuropathic Pain (EASE Pain) Trial: A Randomized Controlled Pilot Trial","EASEPain","Inclusion Criteria:\n\n* Consenting adults 18 years and older.\n* Diagnosis of chronic neuropathic pain (greater than 3 months in duration) by a clinician with specialized training in chronic pain, confirmed with the standardized Leeds Assessment of Neuropathic Symptoms and Signs questionnaire.\n* Suffering from moderate-to-severe pain as defined by\n* Baseline Patient Reported Outcomes Measurement System - Pain Interference (PROMIS-PI) score of greater than or equal to 60\n* An average pain intensity of greater than or equal to 5 on a 0-10 numeric rating scale,43\n* Treatment-refractory pain as defined by a failure of ≥2 medications recommended in the Canadian consensus guidelines on the management of CNP to generate self-reported meaningful improvement in symptoms.\n* For participants of childbearing potential, use of a highly effective or double-barrier methods of contraception. Abstinence is acceptable if it is the preferred and usual lifestyle of the participant.\n* Sufficient English skills to participate in psychotherapy.\n\nExclusion Criteria:\n\n* Past or current history of a psychotic disorder, mania, hypomania, bipolarity, current suicidal ideation, stimulant use disorder (i.e., cocaine, amphetamine, methamphetamine, MDMA, methylphenidate (Ritalin), etc , and any other substance use disorder within the past 12 months assessed by history and confirmed the Mini-International Neuropsychiatric Interview \\[MINI\\]. Other secondary psychiatric comorbidities (e.g., anxiety disorders, trauma related disorders, other personality disorders. etc.) will not be excluded\n* Participants with a history of suicide attempts are not excluded unless a significant risk of suicidal behavior is present at the time of screening as determined by the CRSS (Columbia suicide rating scale)\n* History of prior MDMA use (excluded to maintain blinding integrity)\n* Long QT syndrome, measured by an ECG with a QTc more than 450 ms for males, and 470 ms for females.\n* Presence of a relative or absolute contraindication to MDMA or Methylphenidate:\n* Pre-existing cardiovascular disorders evidenced in clinical records or disclosed on patient self-report, such as: uncontrolled hypertension (sustained blood pressure ≥160\u002F100 mmHg), angina (ongoing angina at rest, recent hospitalization for acute coronary syndrome within the past 3 months, or a history of revascularization (e.g., stenting or bypass surgery) within the past 6 months), arterial occlusive disease; heart failure, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction (within the past 6 months), potentially life-threatening arrhythmias (new-onset within the last 3 months), arrhythmias causing hemodynamic instability (SBP \\\u003C 90 mm Hg), or requiring urgent intervention (e.g., atrial fibrillation with rapid ventricular response or ventricular tachycardia), channelopathies, aneurysmal vascular disease (e.g., thoracic and\u002For abdominal aorta, intracranial, and peripheral arterial vessels), advanced arteriosclerosis\n* Cerebrovascular conditions: acute stroke or recent history of intracerebral hemorrhage (ischemic or hemorrhagic stroke occurring within the past 6 months)\n* Conditions at risk of elevation of blood pressure and increase heart rate, such as glaucoma, tension, agitation, thyrotoxicosis, pheochromocytoma\n* Motor tics and\u002For family history or diagnosis of Tourette's syndrome\n* Moderate to severe chronic kidney disease or kidney failure, such as requiring dialysis, significant treatment adjustments for kidney function, or regular nephrologist follow-up)\n* Moderate to severe liver disease, such as cirrhosis, a history of significant jaundice unrelated to temporary illness, or any liver condition requiring regular monitoring by a specialist).\n* Current treatment with selective serotonin reuptake inhibitors (SSRI's) and serotonin-norepinephrine reuptake inhibitors (SNRI's), tricyclic antidepressants, serotonin 5-HT1 receptor agonists (triptans) and 5-HT3 receptor antagonist antiemetics (risk of Serotonin Syndrome)\n* Hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption (methylphenidate contains lactose)\n* Seizure disorders\n* Pregnancy, or breastfeeding\n* Known hypersensitivity to study drugs or any study drug excipients\n* Medications that interact with study drugs including:\n* Any lifetime history use of any stimulant medication (e.g., Adderall, Vyvanse, Ritalin)\n* Caffeine intake within 24 hours\n* Monoamine oxidase inhibitors (MAOI) within 14 days (e.g. phenelzine, moclobemide, isoniazid, linezolid, phenelzine, harmine) due to risk of hypertensive crisis\n* CYP2D6 substrates and modifiers (such as: buproprion, fluoxetine, paroxetine, duloxetine, mirabegron).\n* Adrenergic agents (e.g. clonidine) risk of sudden death\n* Vasopressor agents (ephedrine pseudoephedrine)\n* Coumarin anticoagulants (e.g., warfarin),\n* Anticonvulsants (e.g., phenobarbital, diphenylhydantoin, primidone)\n* Anti-psychotics and inhibitors of dopamine uptake (e.g. haloperidol, DOPA, tricyclic antidepressants)\n* Concomitant medication that could prolong ECG QT interval (e.g. ondansetron, risperidone, methadone)\n* Selective Serotonin Reuptake Inhibitors (citalopram, sertraline, fluvoxamine, escitalopram)\n* Selective Norepinephrine Uptake Inhibitors (e.g. venlafaxine, duloxetine); Serotonergic Drugs (e.g. dextromethorphan, fentanyl, St. John's Wort, tramadol, 5-hydroxytryptophan); serotonin 5-HT1 receptor agonists (triptans) and 5-HT3 receptor antagonist antiemetics due risk of Serotonin Syndrome which is a potentially life- threatening condition\n* Currently engaged in psychotherapy for CNP (other psychotherapy for non-CNP is allowed).\n* Any other clinically significant medical illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if they take part in the study.",{"count":150,"type":21},50,[152],"PHASE2","This is a Health Canada regulated internal pilot study designed to assess the feasibility, tolerability, and preliminary efficacy of 3, 4-methylenedioxymethamphetamine hydrochloride capsules-AT for chronic neuropathic pain to inform a larger, fully powered multi-center study. This is an interventional, randomized, 2-arm parallel, blinded (Treating and dosing physician, Patient Outcome assessor and psychotherapist).\n\nThe total study duration is 2 years.\n\nParticipants will receive preparatory psychotherapy session during week 2 and week 4 followed by a combined single dosing session with psychotherapy during week 6. Integrative psychotherapy will follow at weeks 6, 8, 12, and 16.\n\nFollow up for primary clinical endpoint at week 16; final follow up for secondary clinical endpoint at 16-weeks.\n\nParticipants will be asked to complete adjunctive home psychotherapy in the form of online modules. Data collected will be entered in electronic case report form (REDCap Academic).",[155],"Chronic Neuropathic Pain",[157,155],"3, 4-methylenedioxymethamphetamine hydrochloride","2026-07-28",{"date":160,"type":43},"2026-07-29",{"date":162,"type":43},"2026-01-30",{"date":164,"type":21},"2028-12-01",{"name":49,"class":50},{"id":167,"slug":168,"hasResults":12,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":175,"briefSummary":177,"conditions":178,"keywords":183,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":84},"100578338","phase-1-contralateral-corticosteroid-injection-in-total-knee-arthroplasty-100578338","NCT06809998","COntralateral CorticoSTeroid Injection in Total Knee Arthroplasty","COSTI: COntralateral CorticoSTeroid Injection in Total Knee Arthroplasty - A Triple Blinded, Randomized Controlled Trial Pilot Study","COSTI","Inclusion Criteria:\n\n* Patients 18 years of age and older\n* Primary osteoarthritis diagnosis with indication for primary elective unilateral TKA\n* No previous contralateral knee injections (steroids\u002Fbiologics) within one year of study\n* Not scheduled for bilateral TKA or a subsequent staged contralateral TKA within the next six months\n* No previous or active infection or trauma (osseous\u002Fligamentous\u002Fextensor mechanism) on the contralateral knee\n* Contralateral knee pain \\& symptoms - defined as a VAS of \\>4\u002F10 at initial pre-op visit\n* Contralateral knee OA quantified as: Kellgren and Lawrence grade \\>2-4\n\n  * Assessed by PI (AK) who will not be contributing any patients to the study through examination of blinded knee radiographs (3 views: AP\u002Flateral\u002FSunrise)\n* Patient is able to read and understand English and provide informed consent to participation in the study\n\nExclusion Criteria:\n\n* Other aetiologies of OA that warrants TKA (inflammatory or post traumatic arthritis)\n* Cognitive impairment (dementia, Alzheimer's, uncontrolled delirium) which will prevent patients from completing primary outcome measure or comply with follow-up requirements\n* Previous TKA or ORIF or nailing on either knee\n* Previous or active knee infection or extensor mechanism disruption\n* Previous arthroscopy on either knee\n* Medical contraindication to elective TKA surgery",{"count":5,"type":21},[176,152],"PHASE1","Through a triple-blinded randomized control trial, the primary purpose of this pilot study is to assess the efficacy of administering peri-operative contralateral corticosteroid injection in patients undergoing TKA. The secondary outcome was to assess the effect of contralateral corticosteroid injection on pain and functional outcomes of patients undergoing TKA.",[179,180,181,182],"Total Knee Anthroplasty","Osteoarthritis(Primary)","Osteoarthritis (OA) of the Knee","Bilateral Knee Osteoarthritis",[172,184,185],"Total Knee Arthroplasty","Corticosteroid Injection",{"date":187,"type":43},"2026-07-30",{"date":189,"type":43},"2025-01-24",{"date":191,"type":21},"2027-08-30",{"name":49,"class":50},{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":200,"sex":17,"minAge":201,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":204,"briefSummary":205,"conditions":206,"keywords":212,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":223},"100649216","national-rapid-tlc-testing-and-linkage-to-care-100649216","NCT07730801","National Rapid TLC: Testing and Linkage to Care","Rapid Testing and Linkage to Care for Underserved and Undiagnosed Populations at Risk of HIV and STBBIs or Living With HIV and STBBIs Across Canada Using the GeneXpert System","Inclusion Criteria:\n\n* Individuals accessing STBBI testing at specific locations who are ≥ 16 years of age\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Unable to provide signed informed consent (e.g., intoxicated)\n* In the opinion of the site PI \u002Fstudy operator, the participant is unable to complete the study elements.\n* Participants who have previously enrolled in the study.",true,"16 Years",{"count":203,"type":21},2500,[96],"The goal of this cross-sectional study is to learn if the GeneXpert system is a practical system for HIV and STBBI testing in community-based organizations and health clinics. The study involves a clinical trial to learn if the HIV-1 Qual XC test works to identify HIV in near-patient settings. The main questions it aims to answer are to create a near-patient testing model for testing and treating patients in a single visit, and to learn if the HIV-1 Qual XC test works to accurately detect HIV in patients. Patients who come to study sites to ask for HIV or STBBI testing will be given the option to participate in the study. Those who agree with provide samples for the tests of their choice and answer survey questions before and after their tests are completed. Those who participate in the clinical trial will have a blood sample sent to provincial labs to compare the results to the HIV -1 Qual XC test. Follow-up visits will be done at 1,3 and 6 months to see if patients completed treatment and\u002For remained connected to care.",[207,208,209,210,211],"HIV","Chlamydia","Gonorrhea","HCV","HPV",[213,214,215],"device trial","Canada","GeneXpert","2026-07-27",{"date":158,"type":43},{"date":219,"type":21},"2026-08-01",{"date":221,"type":21},"2028-03",{"name":49,"class":50},2,{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":234,"briefSummary":235,"conditions":236,"keywords":242,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":84},"100648462","digital-supported-versus-standard-consent-for-advanced-therapeutic-endoscopy-100648462","NCT07723105","Digital-Supported Versus Standard Consent for Advanced Therapeutic Endoscopy","Digital-Supported Versus Standard Informed Consent for Advanced Therapeutic Endoscopy: A Pragmatic Multicenter Randomized Trial","DIGI-CONSENT","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Scheduled to undergo elective advanced therapeutic endoscopy\n* Able to provide informed consent for study participation\n* Able to engage with study materials in a language supported by the site\n* Willing and able to complete study questionnaires and follow-up assessments\n\nExclusion Criteria:\n\n* Emergent or urgent procedures where the consent process cannot reasonably incorporate the study intervention\n* Inability or unwillingness to provide informed consent for study participation\n* Requirement for substitute decision-maker consent for the procedural decision itself, if this precludes meaningful use of the study intervention\n* Severe cognitive, visual, hearing, or communication limitations not adequately accommodated by site resources\n* Inability to complete the planned pre-procedural assessments\n* Prior enrollment in this study for the same procedural episode\n* Any clinical situation in which the treating endoscopist determines that study participation would be unsafe or inappropriate",{"count":233,"type":21},180,[96],"This study will evaluate whether a digital-supported informed consent process improves patient understanding before advanced therapeutic endoscopy procedures.\n\nPatients undergoing advanced therapeutic endoscopy are often asked to make decisions about procedures that may be complex and involve important risks, benefits, and alternatives. Standard informed consent is usually provided through discussion with the treating physician. However, this process can vary between clinicians and may be affected by time pressures in busy endoscopy units.\n\nIn this study, eligible adult patients scheduled for elective advanced therapeutic endoscopy will be randomly assigned to one of two consent pathways. One group will receive standard physician-led informed consent. The other group will receive a digital-supported consent pathway that includes a standardized procedure-specific educational video, an offline artificial intelligence-based question-answering tool, and final confirmation with the treating physician before the procedure.\n\nThe digital tool is designed to provide plain-language information about the procedure, including why it is being done, expected benefits, common and serious risks, alternatives, what to expect before and after the procedure, and the patient's right to ask questions or decline the procedure. The AI question-answering tool will use only investigator-approved educational content and will not provide individualized medical advice. Questions requiring patient-specific medical judgment will be directed back to the treating clinical team.\n\nThe main outcome of the study is patient comprehension of the consent information, measured after the assigned consent process and before the procedure. The study will also evaluate patient anxiety, satisfaction, confidence in decision-making, usability of the consent process, workflow outcomes, and consent-related safety or ethical concerns.",[237,238,239,240,241],"Informed Consent","Patient Education","Patient Comprehension","Therapeutic Endoscopy","Digital Health",[243,244,245,246,247,248,249,250,251,252,253,254,255],"Digital consent","Informed consent","Advanced endoscopy","Therapeutic endoscopy","Patient comprehension","Patient education","Artificial intelligence","AI question-answering tool","Video-based consent","Patient satisfaction","Pre-procedural anxiety","Pragmatic randomized trial","Endoscopy workflow","2026-07-20",{"date":258,"type":43},"2026-07-23",{"date":260,"type":21},"2026-09-01",{"date":262,"type":21},"2028-03-01",{"name":49,"class":50},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":275,"conditions":276,"keywords":280,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":294,"leadSponsor":296,"locationsCount":84},"100645904","cyanoacrylate-glue-versus-absorbable-gelatin-sponge-for-gastric-varices-100645904","NCT07699354","Cyanoacrylate Glue Versus Absorbable Gelatin Sponge for Gastric Varices","Cyanoacrylate Glue Versus Absorbable Gelatin Sponge for Endoscopic Treatment of Gastric Varices (CoAGS-GV): A Randomized, Patient- and Assessor-Blinded, Non-Inferiority Trial","CoAGS-GV","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Gastric varices deemed suitable for EUS-guided endoscopic treatment.\n* History of suspected gastric variceal bleeding or active gastric variceal bleeding, with treatment intended for secondary prophylaxis.\n* Ability to provide informed consent directly or through a substitute decision maker.\n* Willingness and ability to undergo clinical follow-up, EUS assessment, and CT imaging.\n\nExclusion Criteria:\n\n* Inability or unwillingness to provide informed consent directly or through a substitute decision maker.\n* No gastric varix present, or gastric varix too small or not amenable to combination therapy.\n* Contraindication to therapeutic EUS or endoscopy.\n* Contraindication to any study material used in the assigned treatment arm.\n* Contraindication to contrast-enhanced CT, if not clinically manageable.\n* Inability to complete planned follow-up.\n* Pregnancy.\n* Any clinical situation in which the treating endoscopist determines that randomization would be unsafe or inappropriate.",{"count":273,"type":21},64,[96],"This study compares two endoscopic ultrasound-guided treatments for gastric varices, which are enlarged veins in the stomach that can bleed. Both treatments use small coils placed into the varix. One group will receive coils with cyanoacrylate medical glue, and the other group will receive coils with absorbable gelatin sponge.\n\nThe purpose of the study is to determine whether absorbable gelatin sponge with coils is not worse than cyanoacrylate glue with coils for closing off gastric varices, and to compare safety outcomes. Participants will be randomly assigned to one of the two treatment groups. Participants and outcome assessors will not know which treatment was used, but the doctor performing the procedure will know.\n\nAfter the procedure, participants will be followed for up to 12 months. Follow-up may include clinical assessments, questionnaires about health and quality of life, CT imaging shortly after the procedure, and repeat endoscopic ultrasound assessments to evaluate whether the gastric varix has been successfully treated.",[277,278,279],"Gastric Varices Bleeding","Gastric Varices","Portal Hypertension",[281,282,283,284,285,286,287,288,289],"Endoscopic ultrasound","EUS-guided therapy","Portal hypertension","Cyanoacrylate glue","Absorbable gelatin sponge","Gelfoam","Coil embolization","Variceal obliteration","Secondary prophylaxis","2026-07-09",{"date":292,"type":43},"2026-07-13",{"date":219,"type":21},{"date":295,"type":21},"2029-08-01",{"name":49,"class":50},{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":22,"phases":306,"briefSummary":308,"conditions":309,"keywords":313,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":223},"100594271","phase-4-glucagon-like-peptide-1-receptor-agonists-in-patients-receiving-maintenance-dialysis-100594271","NCT07017270","Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis","GUARD-1","Inclusion Criteria:\n\n1. Age ≥ 18\n2. Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days\n3. confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and\u002For insulin.\n4. Ability to provided informed consent or through their substitute decision maker\n\nExclusion Criteria:\n\n1. Type 1 DM\n2. Use of a GLP-1-RA within 30 days prior to screening\n3. Personal or first-degree relative(s) with a history of type 2 multiple endocrine neoplasia syndrome or medullary thyroid cancer, or acute pancreatitis (within 180 days of study screening)\n4. Confirmed pregnancy, women of childbearing potential\n5. Known hypersensitivity to GLP-1-RA\n6. Expected to recover kidney function, stop hemodialysis, pursue palliative care, or transplantation within 6 months\n7. Enrolment in another clinical trial judged by the investigator to interact with the effect of GLP1-RA",{"count":305,"type":21},100,[307],"PHASE4","This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.",[310,311,312,29],"Kidney Disease, Chronic","Diabetes","Dialysis",[312,314,315,34,316,317],"Type 2 diabetes","semaglutide","GLP1","GLP1RA","2026-06-22",{"date":320,"type":43},"2026-06-26",{"date":322,"type":43},"2025-11-27",{"date":324,"type":21},"2027-09",{"name":49,"class":50},{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":336,"briefSummary":337,"conditions":338,"keywords":342,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":84},"100545753","phase-2-psilocybin-assisted-cognitive-processing-therapy-for-chronic-ptsd-100545753","NCT06386003","Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD","Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial","Inclusion Criteria:\n\n1. Meet Diagnostic and Statistical Manual-5th edition (DSM-5) criteria for current PTSD with a duration of 6 months or longer assessed by study psychiatrist;\n2. Have a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score of 50 or higher, indicating moderate to severe PTSD symptoms;\n3. Are willing to refrain from taking any psychiatric medications during the study period.\n\nExclusion Criteria:\n\n1. Are pregnant or nursing, or are women of child bearing potential who are not practicing an effective means of birth control;\n2. Have a history of or a current primary diagnosis of psychotic disorder, schizophrenia, delusional disorder, borderline personality disorder, schizoaffective disorder, bipolar disorder or, dissociative identity disorder;\n3. Have evidence or history of coronary artery disease or cerebral or peripheral vascular disease, hepatic disease with abnormal liver enzymes, or any other medical disorder judged by the investigator to significantly increase the risk of psilocybin administration;\n4. Have hypertension using the standard criteria of the American Heart Association (values of 140\u002F90 or higher assessed on three separate occasions;\n5. History of seizure disorder;\n6. Uncontrolled insulin-dependent diabetes;\n7. Recent stroke, intracranial or subarachnoid hemorrhage (\\\u003C 1 year from signing of informed consent form \\[ICF\\]), recent myocardial infarction (\\\u003C 1 year from signing of ICF), clinically significant arrhythmia (\\\u003C 1 year from signing of ICF);\n8. Have liver disease with the exception of asymptomatic subjects with Hepatitis C who have previously undergone evaluation and successful treatment;\n9. Lifetime history of substance-induced psychosis;\n10. Lifetime history of substance use disorder with a hallucinogen;\n11. History of alcohol use disorder in the past 3 months.","65 Years",{"count":335,"type":21},15,[152],"This is an open-label trial evaluating feasibility, tolerability, safety and efficacy of psilocybin assisted cognitive processing therapy for chronic Posttraumatic Stress Disorder (PTSD).",[339,340,341],"Post Traumatic Stress Disorder","PTSD","Chronic PTSD",[339,343,344],"Psilocybin","Cognitive Processing Therapy",{"date":320,"type":43},{"date":347,"type":21},"2026-06",{"date":349,"type":21},"2027-01",{"name":49,"class":50},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":22,"phases":358,"briefSummary":359,"conditions":360,"keywords":368,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":223},"100622718","mainstreaming-genetics-evaluation-of-a-digital-application-to-scale-and-spread-oncologist-initiated-genetic-testing-100622718","NCT07387263","Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing","Inclusion Criteria:\n\n* Receiving germline testing related to primary cancer condition initiated by oncologist\n* 18 years old or older.\n* Speak and read English\n\nExclusion Criteria:\n\n* Receiving cancer genetic testing via a referral to a genetics clinic\n* Do not speak or read English\n* Under 18 years of age\n* Determined to have diminished, marginal and or fluctuating decisional capacity\n* Lack access to internet or an electronic device",{"count":233,"type":21},[96],"Genetic testing can alter therapy and surgical management for cancer patients and is therefore indicated as a first-line test for many newly diagnosed patients, including breast, ovarian, pancreatic, prostate and colon\u002FGI patients. To reduce pressure on already constrained genetics clinics across Canada, some cancer centres are 'mainstreaming' genetic testing - whereby genetic testing is initiated and mediated by oncologists without traditional pre-test genetic counseling (GC) often using some form of paper-based patient pamphlets or videos. There is no standard, evidence-based approach to mainstreaming, leading to significant practice variation, a lack of coordinated care and ultimately, negative psychological impacts on patients. Digital solutions can address these gaps by providing a standardized, coordinated and patient-centered approach to deliver cancer genetic education. However, digital solutions for providing cancer genetics services are uncommon and clinical-effectiveness and service delivery outcomes have not been well-assessed. This study will test a digital mainstreaming platform called the Genetics Adviser for Mainstream care to assess its effectiveness in improving psychological outcomes and patient-centred care for mainstream cancer patients compared to standard of care.",[361,362,363,364,365,366,367],"Cancer","Breast Cancer","Prostate Cancer","Colon Cancer","GI Cancers","Ovarian Cancer","Pancreatic Cancer",[369,370,371,372,373,361,374,375,376],"Cancer Genetic Testing","Randomized Controlled Trial","Digital Tool","Mainstreaming","Genetic counseling","Genetic testing","Service Delivery","Alternative service delivery model","2026-06-19",{"date":379,"type":43},"2026-06-24",{"date":381,"type":43},"2026-04-30",{"date":383,"type":21},"2027-03",{"name":49,"class":50},{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":200,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":22,"phases":393,"briefSummary":394,"conditions":395,"keywords":402,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":412,"locationsCount":413},"100551076","the-genetics-navigator-evaluating-a-digital-platform-for-genomics-health-services-100551076","NCT06455384","The Genetics Navigator: Evaluating a Digital Platform for Genomics Health Services","Inclusion:\n\n* Adult patients (18 years of age or older) who are referred to participating clinicians at Mount Sinai Hospital for clinical genetic testing.\n* Parents\u002Flegal guardians (18 years of age or older) of pediatric patients who are referred to participating clinicians at SickKids for clinical genetic testing.\n\nExclusion:\n\n* Known not to be eligible for clinical genetic testing in Ontario\n* Requires urgent clinical genetic testing or prenatal genetic testing\n* Not fluent in English (speaking and reading)",{"count":392,"type":21},170,[96],"Genetic testing (GT) (including targeted panels, exome and genome sequencing) is increasingly being used for patient care as it improves diagnosis and health outcomes. In spite of these benefits, genetic testing is a complex and costly health service. This results in unequal access, increased wait times and inconsistencies in care. The use of e-health tools to support genetic testing delivery can result in a better patient experience and reduced distress associated with waiting for results and empower patients to receive and act on medical results. We have previously developed and tested an interactive, adaptable and patient-centred digital decision support tool (Genetics ADvISER) to be used for genetic testing decision making, and have now developed the Genetics Navigator (GN), a patient-centred e-health navigation platform for end-to-end genetic service delivery. The objective of this study is to evaluate the effectiveness of the GN in an RCT in reducing distress with patients and parents of patients being offered genetic testing. Results of this trial will be used to establish whether the GN is effective to use in practice. If effective, GN could fill a critical clinical care gap and improve health outcomes and service use by reducing counselling burden as well as overuse, underuse and misuse of services. These are concerns policy makers seek to address through the triple aims of health care1. This study represents a significant advance in personalized health by assessing the effectiveness of this novel, comprehensive e-health platform to ultimately improve genetic service delivery, accessibility, patient experiences, and patient outcomes.",[396,397,398,399,400,361,401],"Cardiac Conditions","Connective Tissue Diseases","Retinal Disease","Epilepsy in Children","Neurodevelopmental Disorders","Polyposis",[403,370,404,405,406,407],"Genomic Sequencing","Clinical Utility","Personal Utility","Decision Aid","Incidental Findings",{"date":379,"type":43},{"date":410,"type":43},"2025-10-28",{"date":114,"type":21},{"name":49,"class":50},3,{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":422,"enrollmentInfo":423,"targetDuration":4,"studyType":22,"phases":425,"briefSummary":426,"conditions":427,"keywords":430,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":84},"100625180","supporting-social--economic-equity-disrupting-cycles-of-homelessness-and-nurturing-growth--empowerment-100625180","NCT07419282","Supporting Social & Economic Equity, Disrupting Cycles of Homelessness, And Nurturing Growth & Empowerment","Supporting Social & Economic Equity, Disrupting Cycles of Homelessness, And Nurturing Growth & Empowerment (SEED CHANGE): A Mixed Methods Quasi-experimental Trial of Economic, Social, and Identity Capital Supports for Youth Transitioning Out of Homelessness in Ontario, Canada","SEED CHANGE","Inclusion Criteria:\n\n* Aged 18 - 24 years\n* Experienced homelessness (defined as unstable\u002Ftime-limited housing arrangements like shelter stays, foster care, or couch surfing) for at least seven consecutive days in the past year\n* Living in market rent housing (defined as non-subsidized housing, inclusive of both formal and informal rental agreements) in the Greater Toronto Area or Niagara Region for at least one month preceding study start\n* Willing to actively participate in all components of the intervention\n* Able to legally work in Canada (includes having a valid Social Insurance Number)\n* Able to provide free and informed consent\n* Able to understand English well enough to give consent and participate in the intervention and data collection\n\nExclusion Criteria:\n\n* In imminent danger of losing their housing (e.g., facing eviction)\n* Planning to move out of the Greater Toronto Area or Niagara Region in the next 18 months\n* Employed full-time or enrolled in an education or training program that requires a long-term (\\>4 weeks) full-time work placement (coinciding with the duration of the study intervention)\n* Receiving rent subsidies (does not include shelter allowance through social welfare programs such as Ontario Works or the Ontario Disability Support Program)\n* Enrolled in a program or study with features similar to the SEED CHANGE intervention (e.g., 1:1 coaching, supported employment, group program targeting identity\u002Fsocial capital)","24 Years",{"count":424,"type":21},42,[96],"The goal of the SEED CHANGE pilot study is to co-design and test a wraparound intervention for young people transitioning away from homelessness. This study will provide information about the types of supports these young people need to live meaningful and thriving lives, and the best ways to deliver these supports. The main questions it aims to answer are:\n\n* Is the wraparound intervention feasible? (i.e., Will young people engage in the study and supports?)\n* Is the wraparound intervention acceptable? (i.e., Do young people find the supports satisfactory and\u002For beneficial?)\n\nParticipants will engage in an 18-month wraparound intervention including the following supports:\n\n* Job Placement\n* Housing Stabilization Funds\n* Grocery Supplements\n* Community Connections Worker\n* Coaching\n* Tools for Intentional Living Program",[428,429],"Homelessness","Youth",[431,432,433,434,435,436,437,438],"youth","coach","employment","homelessness","transition","socioeconomic inclusion","identity capital","social capital","2026-06-11",{"date":441,"type":43},"2026-06-15",{"date":443,"type":43},"2026-02-25",{"date":445,"type":21},"2029-08",{"name":49,"class":50},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":17,"minAge":455,"maxAge":4,"enrollmentInfo":456,"targetDuration":458,"studyType":459,"phases":4,"briefSummary":460,"conditions":461,"keywords":463,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":84},"100340541","geriatric-acetabular-fractures-open-reduction-internal-fixation-versus-replacement-100340541","NCT03713853","Geriatric Acetabular fracTures: Open Reduction Internal Fixation Versus Replacement","GATOR: Geriatric Acetabular fracTures: Open Reduction Internal Fixation Versus Replacement - A Large Cohort of Acute Open Reduction Internal Fixation (ORIF) Versus Total Hip Arthroplasty for Geriatric Acetabular Fractures","GATOR","Inclusion Criteria:\n\n* 60 years of age or older\n* Isolated and Displaced (more or equal to 2mm on any radiographic view) fracture of the acetabulum\n* Patient requires surgical treatment, either THA+ORIF or ORIF surgeries\n* Fracture is acute (within 3 weeks of injury)\n* Patient was ambulatory (with or without walking aids) prior to their acetabular fracture injury\n* Patient is able to provide informed consent to participation in the study\n* Patient is able to read and understand English\n\nExclusion Criteria:\n\n* Presence of an active or chronic infection around the fracture (soft tissue or bone)\n* Open\u002Fcompound fracture\n* Bilateral acetabular fractures\n* Pathological fracture excluding osteoporosis\n* Periprosthetic fracture (previous arthroplasty or hardware or ORIF in-situ). Hardware (screws or plates or nails or hemi-arthroplasty) on the femoral side are not excluded.\n* Medical or surgical contraindication to surgery\n* Dementia","60 Years",{"count":457,"type":21},104,"24 Months","OBSERVATIONAL","Management of acetabular (hip) fractures in the geriatric population can be very challenging because of pre-existing medical comorbidities, pre-existing osteoporosis and increased risk of mortality.\n\nThe two most common treatment options for acetabular fractures are either surgical fixation using plates and screws to hold the fractured pieces in the correct position until the fracture has healed or surgical fixation in addition to a total hip replacement.\n\nSurgical fixation requires prolonged immobilization of the affected limb (typically around 6-12 weeks post-operatively), which can lead to disability and other complications. Such patients, especially those who are frail and cognitively impaired, are unable to adhere to the immobilization restrictions, leading to an increased risk of fixation failure.\n\nPatients who underwent open reduction internal fixation (ORIF) of an acetabular fracture were reported to have about 25 times greater incidence of hip replacement compared with general population matched controls.\n\nAdditionally, performing a subsequent hip replacement after a previous surgical fixation (ORIF) of an acetabular fracture, especially in the elderly population, can present a number of technical difficulties including; difficult dissection due to previous incision(s) and scarring, dealing with retained hardware, bony deficiency and the possibility of infected hardware.\n\nThe aim of the study is to perform a large cohort study to assess pain and physical function in patients 60 years and older who have sustained an acetabular fracture.",[462],"Acetabular Fracture",[464,465,466,467],"Total hip replacement","Total hip arthroplasty","Open Reduction internal Fixation","Hip fixation","2026-06-10",{"date":470,"type":43},"2026-06-12",{"date":472,"type":21},"2026-12",{"date":474,"type":21},"2030-12",{"name":49,"class":50},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":483,"enrollmentInfo":484,"targetDuration":4,"studyType":22,"phases":485,"briefSummary":486,"conditions":487,"keywords":489,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":4},"100643531","functional-electrical-stimulation-for-mdd-100643531","NCT07629050","Functional Electrical Stimulation for MDD","Functional Electrical Stimulation for Major Depressive Disorder: A Pilot Randomized Control Trial","Inclusion Criteria:\n\nPatients will be included if they:\n\n1. Meet the DSM-5 criteria for unipolar MDD with a current MDE without psychotic features, with ≤ 2 failed treatment trials (non-treatment-resistant depression), validated by MINI done by a trained research assistant.\n2. Have no change in the medication regimen or other forms of treatments (e.g., psychotherapy) for at least 4 weeks (28 days) prior to beginning the study, and have no plan to change them during the 20-session treatment period (14 days), and the 4-week post-treatment observation period. This will be established through self-report, in combination with the ATHF filled out by the participant.\n3. Have an MDD diagnosis as confirmed by the MADRS score of ≥7.\n4. Age group between 18 and 70 years of age\n\nExclusion Criteria:\n\nPatients will be excluded if they:\n\n1. History of epilepsy or seizures.\n2. Damage or dysfunction of facial nerves.\n3. Metallic orthopedic implants in the mouth (e.g., plates or screws).\n4. Current fibromyalgia or currently receiving or have received rTMS within the last 28 days before the screening.\n5. History of treatment-resistant depression (TRD) with history of ECT, Magnetic Seizure Therapy, Intravenous Ketamine use in the past or failure of \\>2 antidepressant treatments of adequate duration and dose during the current episode.\n6. Past or current symptoms of mania, hypomania, mixed episodes, psychotic disorders, obsessive-compulsive disorder, post-traumatic stress disorder, active substance abuse or dependence (excluding nicotine and caffeine), neurodegenerative disease, or dementia. This will be confirmed on the MINI (77) administered by a trained research assistant.\n7. Current suicidal intent or plan as demonstrated by a score of ≥4 on MADRS item 10.\n8. Unable to understand instructions in English.\n9. Unable to produce \"Duchenne marker\" expression with FES, secondary to any type of neurological condition or previous botulinum toxin treatments of facial muscles.","70 Years",{"count":5,"type":21},[96],"This study aims to determine whether Functional Electrical Stimulation (FES) of the facial muscles is a safe and effective treatment for major depressive disorder (MDD).",[488],"MDD",[101,490],"Functional Electrical Stimulation","2026-06-04",{"date":493,"type":43},"2026-06-08",{"date":495,"type":21},"2026-05-25",{"date":497,"type":21},"2029-03-30",{"name":49,"class":50},{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":17,"minAge":507,"maxAge":4,"enrollmentInfo":508,"targetDuration":4,"studyType":22,"phases":510,"briefSummary":511,"conditions":512,"keywords":514,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":84},"100494088","phase-3-the-use-of-tranexamic-acid-in-the-treatment-of-symptomatic-subdural-hematoma-100494088","NCT05713630","The Use of Tranexamic Acid in the Treatment of Symptomatic Subdural Hematoma","TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma","TRACE","Inclusion Criteria:\n\n* Patients aged 45 and older weighing between 45-150 kg diagnosed with symptomatic SDH will be included. SDH is defined as unilateral or bilateral crescentic collection of blood (hyper, iso, or hypodense, or mixed density) of greater than or equals to 8 mm in thickness along the cerebral convexity on CT of the head. Symptomatic SDH patients eligible for inclusion are those with SDH with one or more of the following symptoms attributable to the SDH: headache, gait disturbance, confusion or cognitive decline, limb weakness or numbness\u002Fparesthesia, speech or visual disturbance, drowsiness or impaired consciousness, seizures, impaired cognition, or memory loss at the time of assessment.\n\nExclusion Criteria:\n\n\\- Patients will be excluded for any of the following conditions:\n\n1. Asymptomatic for longer than 72 hours\n2. SDH less than 8 mm in maximal thickness\n3. Have an acutely deteriorating neurological status (e.g., brain herniation with pupillary dilation, aneurysm rupture, etc.) that is likely to be fatal within 6 hours or less due to a predominantly acute SDH\n4. Presence of brain contusion larger than 5 cubic centimeters or subarachnoid hemorrhage (SAH) thicker than 10 mm with Glasgow Coma Scale (GCS)\\\u003C 13\n5. Patients with primarily interhemispheric or tentorial SDH\n6. Hypersensitivity to TXA or any of the placebo ingredients\n7. Pregnancy\n8. Irregular menstrual bleeding with unidentified cause\n9. Known acquired colour vision disturbances\n10. Hematuria caused by renal parenchymal disease\n11. Acute and chronic renal insufficiency indicated by estimated Glomerular Filtration Rate (eGFR) ≤ 30 mL\u002Fmin\n12. Concomitant intake of birth control pill and\u002For hormonal replacement therapy, and anti-inhibitor coagulant concentrates (factor VIII inhibitor bypass activity (FEIBA), factor VII, activated factor IX)\n13. Consumption coagulopathy\u002Fdisseminated intravascular coagulation (DIC) in the last 7 days\n14. Not competent to take study medication properly and regularly or not having access to caregiver that is able to comply with study medication administration\n15. Mechanical heart valve\n16. Liver cirrhosis\n17. Recent venous and\u002For arterial thromboembolism within 6 months of study enrolment\n18. SDH caused by intracranial hypotension\n19. Known thrombophilia (e.g., antiphospholipid syndrome)\n20. Any active malignancy: metastatic cancer systemically or to the brain or a primary malignant brain tumour treated within the last 6 months\n21. Previous enrolment in this trial for a prior episode\n22. Time interval \\>3 days from the time of clinical assessment to eligibility assessment\n23. Patients weighing \\\u003C45 kg or \\>150 kg\n24. Patients received any amount of TXA upon admittance to hospital prior to enrolment","45 Years",{"count":509,"type":21},130,[24],"Subdural hematoma (SDH) is a common condition experienced after head injury. Blood collects on the surface of the brain, causing headaches which can progress to confusion, weakness, or even coma. While patients with SDH often receive surgery, not all patients require surgery right away to ease pressure on the brain. After surgery, there can be up to 30 percent chance of more bleeding and the need for more surgeries. Given this, a drug capable of lowering the chance of more bleeding and speeding the recovery of the patient is highly desirable. In this study, we will test a commonly used, cheap drug called Tranexamic Acid (TXA). While the body stops unwanted and sometimes dangerous bleeding naturally by forming blood clots, TXA stops these blood clots from breaking down, which helps to keep bleeding spots plugged. Our previous study showed that TXA helped speed up patients' recovery; but a larger number of patients is necessary to evaluate how well TXA works to reduce bleeding and improve patient-reported outcomes. In this study, regardless of the need for surgery, half of the patients will be randomly assigned to take TXA, while the other half will take a placebo, which is a look-alike substance that contains no active drug. We will measure multiple outcomes over time to determine if TXA is working and lowers healthcare and personal costs, while also taking blood and surgical samples, to better understand how this drug works in SDH patients.",[513],"Subdural Hematoma",[515,516,517,518,519],"symptomatic subdural hematoma","tranexamic acid","TXA","clinical trial","neurosurgery","2026-05-26",{"date":522,"type":43},"2026-05-29",{"date":524,"type":21},"2026-05-20",{"date":526,"type":21},"2030-12-31",{"name":49,"class":50},{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":534,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":17,"minAge":201,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":22,"phases":537,"briefSummary":538,"conditions":539,"keywords":540,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":550,"locationsCount":84},"100554146","swift-canada-study-of-whole-blood-in-frontline-trauma-100554146","NCT06495294","SWiFT Canada (Study of Whole Blood in Frontline Trauma)","SWiFT Canada (Study of Whole Blood in Frontline Trauma): A Pilot Randomized Controlled Trial Assessing Prehospital Whole Blood Versus Component Therapy in Traumatic Hemorrhage","SWiFTCanada","Inclusion Criteria:\n\n* Patient who has suffered a traumatic injury\n* Attended by a participating Ornge AAS clinical team\n* Requires prehospital blood transfusion to treat major traumatic hemorrhage\n\nExclusion Criteria:\n\n* Pediatric (age \\\u003C16 or transported to pediatric trauma centre \\[if age unknown\\])\n* No intravenous or intraosseous access (should be assessed prior to opening box)\n* Knowledge that patient will object to being given blood transfusion for any reasons\n* Blood already administered on-scene, prior to arrival of the participating Ornge AAS",{"count":5,"type":21},[96],"Traumatic injuries affect people of all ages, races, and socioeconomic backgrounds. The Global Burden of Disease study showed that globally in 2019, there were more than 4.4 million deaths due to injury. Furthermore, unintentional injuries are the leading cause of death for people aged 5-29 years worldwide. Uncontrolled bleeding accounts for a significant proportion of these deaths, with approximately 20% occurring in the first 24 hours and 40% occurring within the first 30 days.\n\nBlood transfusion is a life-saving treatment in the management of bleeding patients until bleeding is controlled in hospital, typically delivered through different blood components (red blood cells, plasma and platelets). These components are derived from a whole blood donation and are stored in separate bags (units). There are challenges in carrying separate blood products, such as additional weight in kit bags, and transfusing multiple blood products at the scene can delay transport to hospital.\n\nIn Ontario, Ornge Air Ambulance carries red blood cells and plasma to transfuse prehospital. However, a prehospital transfusion strategy has not been established and practice varies across the Canadian setting, and more broadly across the world.\n\nThis trial aims to investigate if carrying and transfusing two units of whole blood instead of four units (two red blood cells and two plasma) is feasible and leads to better outcomes for patients.",[100],[541,542,543,544],"prehospital","major hemorrhage","transfusion","emergency medicine",{"date":546,"type":43},"2026-05-06",{"date":548,"type":43},"2024-12-16",{"date":383,"type":21},{"name":49,"class":50},{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":557,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":17,"minAge":333,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":22,"phases":561,"briefSummary":562,"conditions":563,"keywords":565,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":567,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":571,"locationsCount":84},"100368394","diffir---geriatric-distal-femur-fixation-versus-replacement-100368394","NCT04076735","DIFFIR - Geriatric Distal Femur Fixation Versus Replacement","DIFFIR: Geriatric Distal Femur Fixation Versus Replacement - A Randomized Controlled Trial of Acute Open Reduction Internal Fixation (ORIF) Versus Distal Femoral Replacement (DFR)","DIFFIR","Inclusion Criteria:\n\n* Male and female patients\n* 65 years and older\n* Isolated fracture of the distal femur (Classification 33)\n* Fracture is amendable to both treatments\n* Fracture is acute (within 2 weeks from time of injury)\n* Patient was ambulatory (with or without walking aids) prior to the injury\n* Independent or moderately frail with score of 3 to 6 on the Clinical Frailty Scale\n* Patient is able to read and understand English, French, or Spanish\n* Patient or substitute decision maker is able to provide written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Active or previous infection around the fracture (soft tissue or bone)\n* Open fracture\n* Bilateral femur fractures\n* Major vascular injuries requiring intervention, compartment syndrome and major neurologic injuries\n* Pathological fracture excluding osteoporosis\n* Previous surgical fixation or total knee replacement of the distal femur or proximal tibia\n* Previous surgical fixation or hemi\u002Ftotal replacement of the hip\n* Current or previous extensor mechanism (patellar tendon, quadriceps tendon, or patella fracture) disruption or repair\n* Polytrauma (Injury Severity Score \\> 15) or any associated major injuries of the lower extremities\n* Previous medical diagnosis of dementia\n* Medical or surgical contra-indication to surgery",{"count":560,"type":21},140,[96],"The current standard of care for most intra-articular distal femur fractures (above the knee joint) in geriatric patients is a surgical fixation using plates and screws to hold the fracture pieces in the correct position, until the fracture as healed.\n\nHowever, surgical fixation of these complex fractures in geriatric patients, is associated with significant complications, such as non-union (when the broken bone does not heal properly), infection and the need for revision surgery. Additionally, surgical fixation requires prolonged immobilization of of the affected limb (typically around 6-12 weeks post-operatively), which can lead to disability and other complications. Geriatric patients, especially those frail and with cognition impairment, are unable to adhere to the immobilization restrictions, which leads to an increased risk of fixation failure (broken bone does not heal).\n\nAnother treatment option for those patients is an acute distal femoral replacement (artificial knee), where damaged parts of the knee joint are replaced with artificial prosthesis. This procedure allows patients to walk immediately after the surgery and faster return to previous level of function, therefore avoiding the complications for immobilization.\n\nThere is a lack of guideline and evidence to suggest which surgical technique is best to provide superior function outcomes, lower complications and reduced costs. The proposed study seeks to answer this question by performing a large clinical trial comparing knee replacement versus surgical fixation in geriatric patients with distal femur fracture.",[564],"Distal Femur Fracture",[566],"Distal Femur Fracture; Geriatric fracture",{"date":546,"type":43},{"date":569,"type":43},"2021-10-01",{"date":139,"type":21},{"name":49,"class":50},{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":459,"phases":4,"briefSummary":582,"conditions":583,"keywords":586,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":596,"locationsCount":84},"100604828","effects-of-abclo-fascial-approximation-device-in-patients-with-open-abdomen-on-respiratory-mechanics-100604828","NCT07154589","Effects of AbClo Fascial Approximation Device in Patients With Open Abdomen on Respiratory Mechanics","Effects of AbClo Fascial Approximation Device in Patients With Open Abdomen on Respiratory Mechanics (AbClo-Resp)","AbClo-Resp","Inclusion Criteria:\n\n* Adult patients aged 18 years or older\n* Patients admitted to an ICU\n* Patients with postoperative abdominal surgery with open abdomen\n* Patients treated with AbClo device\n* Patients intubated and mechanically ventilated\n* Patients treated with intravenous sedation with a sedation-agitation scale score of 1-3\n\nExclusion Criteria:\n\n* Transient criteria: Patients with severe hemodynamic instability, defined systolic blood pressure less than 75 mmHg or mean arterial pressure less than 60 mmHg despite vasopressor use\n* Transient criteria: Patients with severe bleeding diathesis, defined as the latest platelet count less than 20 · 109\u002FL, or the latest INR higher than 2.0\n* Patients with concurrent injuries to upper gastrointestinal tract that would preclude esophageal balloon insertion\n* Patients with bronchopleural fistula\n* Patients with measured and uncontrolled increased intracranial pressure",{"count":581,"type":21},18,"Patients who underwent an abdominal surgery and had the abdomen remain open are called to have an \"open abdomen\". To limit the risk of further widening of their wounds, surgeons can use AbClo, which is a non-invasive abdominal binding device, to keep the abdominal wall together (i.e., approximate the fascia). However, as the device also compresses on the abdomen and adjacent lungs, this study aims:\n\n* To assess whether the abdominal binding device causes changes in the pressure compressing the lungs, the lung volume, and the function of the lungs.\n* To assess whether adjusting the breathing machine can mitigate such negative changes.\n\nParticipants will already be on the abdominal binding device when joining the study. Measurements on various aspects of the lung function (including its physical properties and capability to oxygenate the blood) will be done before and after adjustment of the abdominal binding device to the pressure (measured in the device itself) recommended by the manufacturer, as well as after the surgery to close the abdomen.",[584,585],"Open Abdomen","Mechanical Ventilation",[587,588,589],"open abdomen","mechanical ventilation","transpulmonary pressure","2026-04-16",{"date":592,"type":43},"2026-04-22",{"date":594,"type":43},"2025-06-10",{"date":347,"type":21},{"name":49,"class":50},{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":601,"acronym":602,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":604,"targetDuration":4,"studyType":22,"phases":606,"briefSummary":607,"conditions":608,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":618},"100497406","type-1-diabetes-virtual-self-management-education-and-support-100497406","NCT05756829","Type 1 Diabetes Virtual Self-management Education and Support","T1ME","Inclusion Criteria:\n\n1. Outpatients ≥18 years of age\n2. Physician diagnosis of type 1 diabetes\n3. Currently on an insulin pump or using multiple daily insulin injections.\n4. HbA1c ≥ 7.5% on most recent laboratory report or estimated from CGM\u002FFGM\\* report, within the last 4 months\n\n   \\*14 day look back window, with a wear rate of 70%, based on Estimated A1c or Glucose management Indicator (GMI)\n5. Has access to a mobile device or computer\u002Ftablet with a video camera\n6. Seen for at least one visit in the previous 6 months by participating certified diabetes educator at the selected diabetes clinic OR If a transitioning patient: Currently enrolled in a diabetes program below AND had at least one visit or touch-point prior in the previous 6 months by participating certified diabetes educator at on of our participating diabetes clinics\n7. OHIP coverage\n8. Currently using an active email address or be willing to obtain an email address\n9. Has consistent and reliable access to internet\n10. Willing and able to comply with scheduled in-person and virtual visits for 6 month intervention period\n\nExclusion Criteria:\n\n1. Diagnosed with non-Type 1 diabetes\n2. Unable to use a computer\u002Ftablet or mobile phone\n3. Pregnant\n4. On dialysis\n5. Unable to fluently speak or read English (self-reported)",{"count":605,"type":21},580,[96],"OVERVIEW: People living with type 1 diabetes (T1D) are expected to fit self-management and regular clinical consultations into busy lives. T1D self-management programs that offer frequent contact with care teams are most effective in helping patients achieve optimal glycemic control. However, this is difficult to deliver in the context of current T1D care which involves time-consuming in-person visits during working hours. The proposed study will test a virtual health care intervention to deliver \"high frequency, low touch\" care aimed at improving metabolic control, while reducing the burden on individuals and their healthcare teams.\n\nSTUDY DESIGN: A pragmatic multicenter, open-label, randomized trial to evaluate the short-term effectiveness of a multifaceted virtual health care intervention in improving glycemic control in individuals with T1D. Planned recruitment is 580 participants from 10 specialized T1D centres in Ontario.\n\nINTERVENTION: Our intervention will include 1) frequent, brief virtual visits between patients with T1D and certified diabetes educators (conducted in real time using a secure telemedicine video interface accessible from any PC, tablet or smart phone) combined with automatic appointment reminders, and 2) a centralized web-based platform to provide educational classes, tools, and resources for diabetes self-management. Virtual visits will be an adjunct to routine in-clinic visits for blood pressure monitoring, foot checks, and surveillance for other complications of diabetes. This approach aims to enable patients to receive more education and support than is feasible in traditional health care models, and in a way that is more seamless (i.e. results in fewer disruptions to their daily life) and tailored to their individual needs based on their stage in life.",[609],"type1diabetes","2026-04-15",{"date":612,"type":43},"2026-04-21",{"date":614,"type":43},"2023-05-10",{"date":616,"type":21},"2027-03-31",{"name":49,"class":50},9,{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":623,"acronym":4,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":625,"targetDuration":4,"studyType":22,"phases":627,"briefSummary":628,"conditions":629,"keywords":634,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":4},"100631955","phase-4-innovative-sternal-closure-techniques-evaluating-stratafix-and-dermabond-for-reduced-complications-in-cabg-patients-100631955","NCT07507409","Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients","Inclusion Criteria:\n\n\\- Patients aged 18 years and older undergoing CABG surgery.\n\nExclusion Criteria:\n\n* Patients who refuse to participate in the trial.\n* Patients who do not read or speak English.\n* Patient with allergy to surgical adhesives or sutures",{"count":626,"type":21},401,[307],"The goal of this clinical trial is to learn if a new method of closing the breastbone after heart bypass surgery can improve healing and reduce complications in adults undergoing coronary artery bypass graft (CABG) surgery.\n\nThe main questions it aims to answer are:\n\nDoes this new closure method reduce infections and wound reopening? Does it improve healing, recovery, and overall patient outcomes?\n\nResearchers will compare patients who receive the new closure method to past patients who received the standard method to see if outcomes are better.\n\nParticipants will:\n\nReceive the new closure method during their surgery (as part of standard care) Be followed during their normal recovery up to their 6-week follow-up visit Complete a short quality-of-life questionnaire (about 10 minutes) Have their recovery assessed, including healing, complications, and hospital use\n\nResearchers will also look at quality of life, heart complications, hospital readmissions, antibiotic use, scar appearance, and overall costs to understand the full impact of the new method.",[630,631,632,633],"Cardiovascular Disease","Surgical Site Infection","Superficial Sternal Wound Infection","Mediastinitis",[635,636,637,638,639],"STRATAFIX","DERMABOND","Sternal Closure","Suture","CABG","2026-04-07",{"date":642,"type":43},"2026-04-13",{"date":644,"type":21},"2026-05-01",{"date":646,"type":21},"2028-05-01",{"name":49,"class":50},{"id":649,"slug":650,"hasResults":12,"nctId":651,"briefTitle":652,"officialTitle":653,"acronym":4,"eligibilityCriteria":654,"healthyVolunteers":12,"sex":655,"minAge":18,"maxAge":656,"enrollmentInfo":657,"targetDuration":4,"studyType":22,"phases":659,"briefSummary":660,"conditions":661,"keywords":664,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":666,"lastUpdatePostDateStruct":667,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":4},"100631477","virtual-mindfulness-and-endometriosis-100631477","NCT07501182","Virtual Mindfulness and Endometriosis","Virtual Mindfulness-Based Therapy for the Management of Endometriosis Chronic Pelvic Pain: A Randomized Control Trial","Inclusion Criteria:\n\n1\\. Be between the ages of 18 and 50; 2. Have been symptomatic for six months or greater; 3. Clinical or surgical diagnosis of endometriosis (must have at least one of the following): i) Documented Clinical Diagnosis of endometriosis based on symptoms ii) Previous endometriosis surgery confirmed by histopathology iii) Imaging suggestive of endometriosis (ultrasound or MRI) iv) Receiving standard medical treatment for endometriosis including combined oral contraceptives, progestin, GnRH agonists, GnRH antagonist.\n\nExclusion Criteria:\n\n1. Diagnosis of other chronic pain condition, other than endometriosis;\n2. Recent surgical cases (\\\u003C 6 months)\n3. Vulvar pain diagnosis including vulvodynia, vaginismus\n4. Changes to current medical treatment or surgical intervention for endometriosis during the workshop period (10 weeks)\n5. Inability to complete the survey package\n6. Currently practicing mindfulness meditation.\n7. Have used the MyEndo phone application previously\n8. No internet access\n9. Non-English speaking.\n10. Unable to consent.","FEMALE","50 Years",{"count":658,"type":21},124,[96],"Endometriosis is a common gynecologic disease affecting 5-10% of women during their reproductive years.1 Symptoms are variable but can include debilitating pelvic pain, pain with intercourse, menstrual cycles, bowel movements and urination. This can interfere with patients' ability to work, attend school or have intimate relationships leading to serious effects on quality of life and mental health.2-5 Current management of endometriosis is predominantly medical and surgical. Unfortunately, these medications can come with potent side effects that may be intolerable to some patients. They can also be prohibitively expensive for patients without prescription coverage. Mindfulness is a psychological approach to bring the mind to the present moment and to enhance self-awareness. It includes the use of emotional regulation, reduced reactivity, and enhanced response flexibility.6 Mindfulness-based psychological treatments have shown to improve both pain and quality of life in patients with chronic pelvic pain.7-9 Despite the evidence for mindfulness-based therapy there is still limited use of this in the treatment of pelvic pain. The reasons for this are multifactorial and include financial and accessibility barriers. Virtual platforms can help bridge these inequities and support marginalized patient populations in getting access to treatments for endometriosis pain. Virtual mindfulness resources have been shown to improve health and decrease stress, anxiety, and depression.10,11 There is minimal evidence about online mindfulness platforms for chronic pain and none relating to endometriosis. There is great potential to use this medium to overcome many barriers to access, but more research is needed on its effectiveness in treating endometriosis pain. The primary objective of this research study is to determine if virtual mindfulness-based therapy improves quality of life in patients with endometriosis following completion of the ten-week virtual mindfulness-based workshop.",[662,663],"Endometriosis","Chronic Pain",[662,663,665],"Virtual Mindfulness","2026-03-24",{"date":668,"type":43},"2026-03-30",{"date":670,"type":21},"2026-03",{"date":672,"type":21},"2027-12",{"name":49,"class":50},{"id":675,"slug":676,"hasResults":12,"nctId":677,"briefTitle":678,"officialTitle":679,"acronym":4,"eligibilityCriteria":680,"healthyVolunteers":200,"sex":17,"minAge":681,"maxAge":682,"enrollmentInfo":683,"targetDuration":4,"studyType":459,"phases":4,"briefSummary":685,"conditions":686,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":688,"lastUpdatePostDateStruct":689,"startDateStruct":691,"completionDateStruct":693,"leadSponsor":695,"locationsCount":84},"100327032","characterizing-dopamine-receptor-binding-in-treatment-resistant-depression-100327032","NCT03537794","Characterizing Dopamine Receptor Binding in Treatment Resistant Depression","Characterizing Dopamine D2 and D3 Receptor Binding in Treatment Resistant Depression","Inclusion Criteria:\n\n* Key inclusion criteria for the MDD patients:\n\n  * DSM-5 criteria for a Major Depressive Episode (MDE) within a MDD, confirmed through MINI diagnosis (Sheehan et al, 2015)\n  * Age between 25 and 55 years\n  * Hamilton Depression Rating Scale - 17 item (HRSD-17; Hamilton, 1960) \\> 14 (moderate to severe symptoms)\n  * Free of psychotropic medications for at least 5 half-lives before PET scanning\n  * Ability to undergo MRI scanning (absence of metal, pacemakers, etc.)\n  * For non-resistant patients: Previous history of response to an antidepressant, in order to increase signal to noise between resistant and non-resistant patients\n\nKey inclusion criteria for the Healthy Controls:\n\n* Ages between 25 and 55 years\n* Ability to undergo MRI scanning (absence of metal, pacemakers, etc.)\n\nExclusion Criteria:\n\nKey exclusion criteria for the MDD patients:\n\n* Pregnancy\u002Flactation\n* Medical condition requiring immediate investigation or treatment\n* Recent (\\\u003C 6 months)\u002Fcurrent history of drug abuse\u002Fdependence\n* Lifetime history of psychosis, other Axis I comorbidities are allowable\n* Use of any psychotropic use within 5 half-lives before the PET scanning\n* For non-resistant patients: Failure of \\> 2 antidepressant treatments of adequate dose and duration for current MDE.\n\nKey exclusion criteria for the Healthy Controls:\n\n* Pregnancy\u002Flactation\n* Medical condition requiring immediate investigation or treatment\n* Lifetime history of any psychiatric disorder\n* Lifetime history of receiving an antidepressant","25 Years","55 Years",{"count":684,"type":21},45,"It is estimated that 30% of individuals with Major Depressive Disorder (MDD) fail to respond to conventional antidepressant medication which accounts for over 1 million Canadians in their lifetime. Treatment resistant depression (TRD) patients also have greater psychiatric and medical comorbidity, poorer quality of life and increased suicidal ideation. Yet, there are few treatment strategies available to target TRD and there is a significant lack of evidence about how TRD differs from treatment-responsive depression. This proposal represents the first study to elucidate the neurobiology of TRD with a focus on dopamine receptor function throughout the brain, in order to inform treatment development and clinical characterization of TRD.The ultimate goal of this unique study is to characterize striatal and extrastriatal dopamine D2 and D3 receptor binding potential in patients with TRD, non-resistant MDD and healthy controls. The primary hypothesis is that TRD patients will exhibit greater D2\u002FD3 receptor binding potential compared to non-TRD patients in the following regions of interest: dorsolateral prefrontal cortex, orbitofrontal cortex, and ventral striatum. Secondarily, non-TRD patients will also demonstrate increased binding potential compared to healthy controls in the same brain regions. Whole brain analyses will allow us to take an exploratory approach to other brain regions that may differentiate TRD from non-TRD patients. Participants will be assessed at St. Michael's Hospital (SMH) and the Centre for Addiction and Mental Health (CAMH), which are within a 10 minute driving distance of each other. There will be 3 study visits following written informed consent. Eligibility will be confirmed at a screening visit at SMH where demographic information, including age, sex, education, and medication history will be obtained, as well as the administration of a structured Mini-International Neuropsychiatric Interview (MINI) for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Axis I diagnoses (Sheehan et al, 2015), and an HRSD-17. Within two weeks of the screening visit, participants will undergo a structural magnetic resonance imaging (MRI) scan at SMH prior to the positron-emission tomography (PET) scan at CAMH. The order of the PHNO scans will be counterbalanced.",[687],"Treatment Resistant Depression","2026-03-12",{"date":690,"type":43},"2026-03-16",{"date":692,"type":43},"2025-08-22",{"date":694,"type":21},"2028-12",{"name":49,"class":50},{"id":697,"slug":698,"hasResults":12,"nctId":699,"briefTitle":700,"officialTitle":700,"acronym":4,"eligibilityCriteria":701,"healthyVolunteers":12,"sex":17,"minAge":702,"maxAge":703,"enrollmentInfo":704,"targetDuration":4,"studyType":22,"phases":705,"briefSummary":706,"conditions":707,"keywords":709,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":713,"lastUpdatePostDateStruct":714,"startDateStruct":716,"completionDateStruct":718,"leadSponsor":720,"locationsCount":4},"100627965","first-appendectomy-using-revolve-surgical-robotic-arm-100627965","NCT07455487","First Appendectomy Using Revolve Surgical Robotic Arm","Inclusion Criteria:\n\n* Inpatients at Unity Health Toronto - St. Michael's Hospital scheduled for an elective appendectomy\n* Ages of 21-40 years old\n* Male and non-pregnant female patients (pregnancy test required)\n* No co-morbidities\n* Body Mass Index (BMI) between 18.5 and 25kg\u002Fm2\n* On no medications\n* Not taking any recreational drugs\n* Uncomplicated acute appendicitis (confirmed through abdominal ultrasound or abdominal computed tomography (CT) scan)\n* The pre-operative white blood cell count (WBC) must be between 4,500 - 15,000 cells per microliter.\n\nExclusion Criteria:\n\n* Any patient who does not have all the inclusion criteria described above.\n* Imaging of perforated appendix, free air, phlegmon, abscess, fluid collection, other any abdominal disease.\n* Any other abnormal laboratory test performed pre-operatively will cause the exclusion of the patient from the study.","21 Years","40 Years",{"count":413,"type":21},[96],"This study is testing a new surgical device called the Revolve Surgical System (RSS) during appendix removal surgery. The RSS is designed to help surgeons perform minimally invasive surgery with improved precision and stability while working at the patient's bedside, similar to standard laparoscopic surgery but with robotic assistance.\n\nThis will be the first time the device is used in patients. It will be evaluated in three adults with uncomplicated appendicitis who are already scheduled to have an appendectomy. The purpose of the study is to assess whether the device can be used safely and effectively and to better understand how it performs during surgery.",[708],"Appendicitis Acute",[710,711,712],"Robotics","Appendicitis","Laparoscopy","2026-03-02",{"date":715,"type":43},"2026-03-06",{"date":717,"type":21},"2026-04-01",{"date":719,"type":21},"2027-01-01",{"name":49,"class":50},""]